EFFECTS OF FONDAPARINUX AND RIVAROXABAN ON CLOT FORMATION IN FACTOR VIII-DEFICIENT, BUT VON WILLEBRAND FACTOR-SUPPLEMENTED, PLASMA MIMICKING PLASMA SAMPLES OBTAINED FROM HEMOPHILIA A PATIENTS

被引：0

作者：

Xu, Zhuo Luan ^{[1
,2
]}

Gantioqui, Jorell ^{[1
]}

Stevic, Ivan ^{[3
]}

Chan, Anthony ^{[1
,4
]}

Chan, Howard H. ^{[1
,5
]}

机构：

[1] McMaster Univ, Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada

[2] McMaster Univ, Fac Hlth Sci, Med Sci Grad Program, Hamilton, ON, Canada

[3] Univ Manitoba, Clin Biochem, Winnipeg, MB, Canada

[4] McMaster Univ, Dept Pediat, Div Hematol Oncol, Hamilton, ON, Canada

[5] McMaster Univ, Dept Med, Div Hematol, Hamilton, ON, Canada

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2016年 / 91卷 / 09期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

F29

引用

页码：E409 / E409

页数：1

共 50 条

[41] Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/Factor VIII Concentrate Among Von Willebrand Disease Patients across All ABO Antigen Blood Groups
Sidonio Jr, Robert F.
BLOOD, 2024, 144 : 3985 - 3985
[42] Plasma-derived, purified, pasteurised von Willebrand factor/factor VIII concentrate in the treatment of patients with von Willebrand disease and haemophilia a: update of a long-term observational study
Wermes, C.
Holzhauer, S.
Halimeh, S.
Kemkes-Matthes, B.
Sommerer, P.
Wieland, I
Krause, M.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 497 - 497
[43] Immune tolerance with a high purity plasma derived factor VIII containing von Willebrand factor in haemophilia A patients with high responding inhibitors.
Polack, B
Beurrier, P
Rothschild, C
Orsini, F
Faradji, A
Liennhard, A
Fressinaud, E
Goudemand, J
BLOOD, 2004, 104 (11) : 846A - 846A
[44] Trial Results Reveal Greater Risk of Inhibitor Formation in Patients With Hemophilia A Receiving Recombinant Factor VIII Than in Patients Receiving Plasma-Derived Factor VIII
不详
AMERICAN JOURNAL OF MANAGED CARE, 2016, 22 : 20 - 21
[45] STRUCTURE - FUNCTION RELATIONSHIP OF FACTOR-VIII-VON WILLEBRAND FACTOR - APPLICATION TO THE STUDY OF VARIANT VON WILLEBRANDS DISEASE AND CRYOSUPERNATANT PREPARED FROM NORMAL PLASMA
PIETU, G
OBERT, B
LARRIEU, MJ
MEYER, D
THROMBOSIS RESEARCH, 1980, 19 (4-5) : 671 - 685
[46] DDAVP-induced rise in pre-infusion von willebrand factor levels may slightly affect the pharmacokinetics of plasma-derived factor VIII concentrate in severe hemophilia A patients
Stokhuijzen, E.
Loomans, J., I
Peters, M.
Fijnvandraat, K.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 594 - 595
[47] RELATIVE ROLES OF PLASMA AND PLATELET VON-WILLEBRAND-FACTOR LEVELS ON DEFECTIVE HEMOSTASIS IN VON-WILLEBRAND DISEASE - EVIDENCE FROM TRANSFUSION STUDIES IN SEVERELY DEFICIENT PATIENTS
CASTILLO, R
ESCOLAR, G
MONTEAGUDO, J
AZNARSALATTI, J
REVERTER, JC
ORDINAS, A
THROMBOSIS AND HAEMOSTASIS, 1993, 69 (06) : 947 - 947
[48] Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients
Deitcher, SR
Tuller, J
Johnson, JA
HAEMOPHILIA, 1999, 5 (02) : 88 - 95
[49] Viral Inactivation and Enrichment of Factor VIII, Factor XIII, Fibrinogen and Von Willebrand Factor (VWF) Multimers from Fresh Frozen Plasma (FFP) Using, "VIPS Plasma, Virus Inactivation Treatment System".
Nepal, Bipin
TRANSFUSION, 2017, 57 : 94A - 94A
[50] VIRAL INACTIVATION AND ENRICHMENT OF FACTOR VIII, FACTOR XIII, FIBRINOGEN AND VON WILLEBRAND FACTOR (VWF) MULTIMERS FROM FRESH FROZEN PLASMA (FFP) USING VIPS PLASMA, VIRUS INACTIVATION TREATMENT SYSTEM
Nepal, B.
Mughal, N.
LEUKEMIA RESEARCH, 2016, 49 : S23 - S24

← 1 2 3 4 5 →